US 10,293,020 B2Granted

Peptide therapeutics and methods for using same

AssigneeStealth BioTherapeutics Inc.

InventorD. Travis Wilson

Life of this patent

Estimating the term…

Abstract

Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of an MPP, and/or naturally or artificially occurring variants or analogs of an MPP, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide such as D-Arg-2′6′-Dmt-Lys-Phe-NH2).

Claims5

Dependent claims

A composition comprising the mitochondria penetrating peptide (MPP) Cha-Arg-Cha-Lys-NH2 alone or in combination with one or more aromatic-cationic peptides selected from the group consisting of:

2′6′-Dmp-D-Arg-2′6′-Dmt-Lys-NH2;
2′,6′-Dmt-D-Arg-Phe-Lys-NH2;
2′6′-Dmp-D-Arg-Phe-Lys-NH2;
2′6′-Dmt-D-Arg-PheOrn-NH2;
2′6′-Dmt-D-Arg-Phe-Ahp(2-aminoheptanoicacid)-NH2;
2′6′-Dmt-D-Arg-Phe-Lys-NH2;
2′6′-Dmt-D-Cit-PheLys-NH2;
Ala-D-Phe-D-Arg-Tyr-Lys-D-Trp-His-D-Tyr-Gly-Phe;
Arg-D-Dmt-Arg-NH2;
Arg-D-Dmt-Lys-NH2;
Arg-D-Dmt-NH2;
Arg-D-Leu-D-Tyr-Phe-Lys-Glu-D-Lys-Arg-D-Trp-Lys-D-Phe-Tyr-D-Arg-Gly;
Arg-D-Tyr-Arg-NH2;
Arg-D-Tyr-Lys-NH2;
Arg-D-Tyr-NH2;
Asp-Arg-D-Phe-Cys-Phe-D-Arg-D-Lys-Tyr-Arg-D-Tyr-Trp-D-His-Tyr-D-Phe-Lys-Phe;
Asp-D-Trp-Lys-Tyr-D-His-Phe-Arg-D-Gly-Lys-NH2;
D-Arg-2′6′-Dmt-Lys-Phe-NH2;
D-Arg-Arg-Dmt-Phe-NH2;
D-Arg-Arg-Tyr-Phe-NH2;
D-Arg-Cha-Lys-Cha-NH2;
D-Arg-Cha-Lys-NH2;
D-Arg-D-Dmt-NH2;
D-Arg-Dmt-D-Lys-Phe-NH2;
D-Arg-Dmt-Lys-Dmt-Lys-Met-NH2;
D-Arg-Dmt-Lys-Dmt-Lys-Trp-NH2;
D-Arg-Dmt-Lys-D-Phe-NH2;
D-Arg-Dmt-Lys-NH2;
D-Arg-Dmt-Lys-Phe-Lys-Met-NH2;
D-Arg-Dmt-Lys-Phe-Lys-Trp-NH2;
D-Arg-Dmt-Lys-Phe-Met-NH2;
D-Arg-Dmt-Lys-Trp-NH2;
D-Arg-Dmt-NH2;
D-Arg-Dmt-Phe-NH2;
D-Arg-D-Tyr-D-Lys-D-Phe-NH2;
D-Arg-D-Tyr-Lys-Phe-NH2;
D-Arg-D-Tyr-NH2;
D-Arg-Phe-Lys-NH2;
D-Arg-Trp-Lys-NH2;
D-Arg-Trp-Lys-Trp-NH2;
D-Arg-Tyr-D-Lys-Phe-NH2;
D-Arg-Tyr-Lys-D-Phe-NH2;
D-Arg-Tyr-Lys-NH2;
D-Arg-Tyr-Lys-Phe-NH2;
D-Arg-Tyr-NH2;
D-Arg-Tyr-Phe-NH2;
D-Dmt-Arg-NH2;
D-Glu-Asp-Lys-D-Arg-D-His-Phe-Phe-D-Val-Tyr-Arg-Tyr-D-Tyr-Arg-His-Phe-NH2;
D-His-Glu-Lys-Tyr-D-Phe-Arg;
D-His-Lys-Tyr-D-Phe-Glu-D-Asp-D-Asp-D-His-D-Lys-Arg-Trp-NH2;
Dmt-D-Arg-NH2;
Dmt-D-Phe-Arg-Lys-NH2;
Dmt-Lys-D-Phe-NH2;
Dmt-Lys-NH2;
Dmt-Lys-Phe-NH2;
D-Nle-Cha-Ahe-Cha-NH2;
D-Nle-Dmt-Ahe-Phe-NH2;
D-Phe-D-Arg-D-Phe-D-Lys-NH2;
D-Tyr-Arg-NH2;
D-Tyr-Trp-Lys-NH2;
Glu-Arg-D-Lys-Tyr-D-Val-Phe-D-His-Trp-Arg-D-Gly-Tyr-Arg-D-Met-NH2;
Gly-Ala-Lys-Phe-D-Lys-Glu-Arg-Tyr-His-D-Arg-D-Arg-Asp-Tyr-Trp-D-His-Trp-His-D-Lys-Asp;
Gly-D-Phe-Lys-His-D-Arg-Tyr-NH2;
H-D-Arg(NαMe)-Dmt(NMe)-Lys(NαMe)-Phe(NMe)-NH2;
H-D-Arg-Dmt-Lys(NαMe)-Phe(NMe)-NH2;
H-D-Arg-Dmt-Lys(NαMe)-Phe-NH2;
H-D-Arg-Dmt-Lys-Phe(NMe)-NH2;
H-D-Arg-Dmt-Lys-Phe-Sar-Gly-Cys-NH2;
H-D-Arg-Dmt-LysΨ[CH2-NH]Phe-NH2;
H-D-Arg-Dmt-Ψ[CH2-NH]Lys-Phe-NH2;
H-D-Arg-Dmt-Ψ[CH2-NH]Lys-Ψ[CH2-NH]Phe-NH2;
H-D-Arg-Ψ[CH2-NH]Dmt-Lys-Phe-NH2;
His-Tyr-D-Arg-Trp-Lys-Phe-D-Asp-Ala-Arg-Cys-D-Tyr-His-Phe-D-Lys-Tyr-His-Ser-NH2;
Lys-D-Arg-Tyr-NH2;
Lys-D-Gln-Tyr-Arg-D-Phe-Trp-NH2;
Lys-Dmt-D-Arg-NH2;
Lys-D-Phe-Arg-Dmt-NH2;
Lys-D-Phe-Arg-Tyr-NH2;
Lys-Phe-NH2;
Lys-Trp-D-Tyr-Arg-Asn-Phe-Tyr-D-His-NH2;
Met-Tyr-D-Arg-Phe-Arg-NH2;
Met-Tyr-D-Lys-Phe-Arg;
Phe-Arg-D-His-Asp;
Phe-D-Arg-2′6′-Dmt-Lys-NH2;
Phe-D-Arg-D-Phe-Lys-NH2;
Phe-D-Arg-His;
Phe-D-Arg-Lys-Trp-Tyr-D-Arg-His;
Phe-D-Arg-Phe-D-Lys-NH2;
Phe-D-Arg-Phe-Lys-NH2;
Phe-D-Dmt-Arg-Lys-NH2;
Phe-D-Tyr-Arg-Lys-NH2;
Phe-Lys-Dmt-NH2;
Phe-Phe-D-Tyr-Arg-Glu-Asp-D-Lys-Arg-D-Arg-His-Phe-NH2;
Phe-Tyr-Lys-D-Arg-Trp-His-D-Lys-D-Lys-Glu-Arg-D-Tyr-Thr;
Thr-Gly-Tyr-Arg-D-His-Phe-Trp-D-His-Lys;
Thr-Tyr-Arg-D-Lys-Trp-Tyr-Glu-Asp-D-Lys-D-Arg-His-Phe-D-Tyr-Gly-Val-Ile-D-His-Arg-Tyr-Lys-NH2;
Trp-D-Lys-Tyr-Arg-NH2;
Trp-Lys-Phe-D-Asp-Arg-Tyr-D-His-Lys;
Tyr-Asp-D-Lys-Tyr-Phe-D-Lys-D-Arg-Phe-Pro-D-Tyr-His-Lys;
Tyr-D-Arg-NH2;
Tyr-D-Arg-Phe-Lys-Glu-NH2;
Tyr-D-Arg-Phe-Lys-NH2;
Tyr-D-His-Phe-D-Arg-Asp-Lys-D-Arg-His-Trp-D-His-Phe;
Tyr-D-Phe-Arg-Lys-NH2;
Tyr-His-D-Gly-Met;
and
Val-D-Lys-His-Tyr-D-Phe-Ser-Tyr-Arg-NH2,
and further comprising one or more additional active agents selected from the group consisting of cyclosporine, a cardiac drug, an anti-inflammatory, an anti-hypertensive drug, an antibody, an ophthalmic drug, an antioxidant, a metal complexer, and an antihistamine.

105 more elements

Dependencies are inferred from the claim text.

Facts

Application: 14/899,439Filed 24 Jun 2014 · us provisional application
Priority: 27 Jun 2013
Published: US 2016/0151446 A12 Jun 2016
Granted: 21 May 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 38/07
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: tetrapeptides
A61K 38/05
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: dipeptides
A61K 38/06
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: tripeptides
A61K 38/08
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: peptides having 5 to 11 amino acids

Family

Application61/840,317Us provisional application · filed 27 Jun 2013
US 2016/0151446 A1Pre-grant publication · published 2 Jun 2016
US 10,293,020 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

A composition comprising the mitochondria penetrating peptide (MPP) Cha-Arg-Cha-Lys-NH2 alone or in combination with one or more aromatic-cationic peptides selected from the group consisting of:

2′6′-Dmp-D-Arg-2′6′-Dmt-Lys-NH2;
2′,6′-Dmt-D-Arg-Phe-Lys-NH2;
2′6′-Dmp-D-Arg-Phe-Lys-NH2;
2′6′-Dmt-D-Arg-PheOrn-NH2;
2′6′-Dmt-D-Arg-Phe-Ahp(2-aminoheptanoicacid)-NH2;
2′6′-Dmt-D-Arg-Phe-Lys-NH2;
2′6′-Dmt-D-Cit-PheLys-NH2;
Ala-D-Phe-D-Arg-Tyr-Lys-D-Trp-His-D-Tyr-Gly-Phe;
Arg-D-Dmt-Arg-NH2;
Arg-D-Dmt-Lys-NH2;
Arg-D-Dmt-NH2;
Arg-D-Leu-D-Tyr-Phe-Lys-Glu-D-Lys-Arg-D-Trp-Lys-D-Phe-Tyr-D-Arg-Gly;
Arg-D-Tyr-Arg-NH2;
Arg-D-Tyr-Lys-NH2;
Arg-D-Tyr-NH2;
Asp-Arg-D-Phe-Cys-Phe-D-Arg-D-Lys-Tyr-Arg-D-Tyr-Trp-D-His-Tyr-D-Phe-Lys-Phe;
Asp-D-Trp-Lys-Tyr-D-His-Phe-Arg-D-Gly-Lys-NH2;
D-Arg-2′6′-Dmt-Lys-Phe-NH2;
D-Arg-Arg-Dmt-Phe-NH2;
D-Arg-Arg-Tyr-Phe-NH2;
D-Arg-Cha-Lys-Cha-NH2;
D-Arg-Cha-Lys-NH2;
D-Arg-D-Dmt-NH2;
D-Arg-Dmt-D-Lys-Phe-NH2;
D-Arg-Dmt-Lys-Dmt-Lys-Met-NH2;
D-Arg-Dmt-Lys-Dmt-Lys-Trp-NH2;
D-Arg-Dmt-Lys-D-Phe-NH2;
D-Arg-Dmt-Lys-NH2;
D-Arg-Dmt-Lys-Phe-Lys-Met-NH2;
D-Arg-Dmt-Lys-Phe-Lys-Trp-NH2;
D-Arg-Dmt-Lys-Phe-Met-NH2;
D-Arg-Dmt-Lys-Trp-NH2;
D-Arg-Dmt-NH2;
D-Arg-Dmt-Phe-NH2;
D-Arg-D-Tyr-D-Lys-D-Phe-NH2;
D-Arg-D-Tyr-Lys-Phe-NH2;
D-Arg-D-Tyr-NH2;
D-Arg-Phe-Lys-NH2;
D-Arg-Trp-Lys-NH2;
D-Arg-Trp-Lys-Trp-NH2;
D-Arg-Tyr-D-Lys-Phe-NH2;
D-Arg-Tyr-Lys-D-Phe-NH2;
D-Arg-Tyr-Lys-NH2;
D-Arg-Tyr-Lys-Phe-NH2;
D-Arg-Tyr-NH2;
D-Arg-Tyr-Phe-NH2;
D-Dmt-Arg-NH2;
D-Glu-Asp-Lys-D-Arg-D-His-Phe-Phe-D-Val-Tyr-Arg-Tyr-D-Tyr-Arg-His-Phe-NH2;
D-His-Glu-Lys-Tyr-D-Phe-Arg;
D-His-Lys-Tyr-D-Phe-Glu-D-Asp-D-Asp-D-His-D-Lys-Arg-Trp-NH2;
Dmt-D-Arg-NH2;
Dmt-D-Phe-Arg-Lys-NH2;
Dmt-Lys-D-Phe-NH2;
Dmt-Lys-NH2;
Dmt-Lys-Phe-NH2;
D-Nle-Cha-Ahe-Cha-NH2;
D-Nle-Dmt-Ahe-Phe-NH2;
D-Phe-D-Arg-D-Phe-D-Lys-NH2;
D-Tyr-Arg-NH2;
D-Tyr-Trp-Lys-NH2;
Glu-Arg-D-Lys-Tyr-D-Val-Phe-D-His-Trp-Arg-D-Gly-Tyr-Arg-D-Met-NH2;
Gly-Ala-Lys-Phe-D-Lys-Glu-Arg-Tyr-His-D-Arg-D-Arg-Asp-Tyr-Trp-D-His-Trp-His-D-Lys-Asp;
Gly-D-Phe-Lys-His-D-Arg-Tyr-NH2;
H-D-Arg(NαMe)-Dmt(NMe)-Lys(NαMe)-Phe(NMe)-NH2;
H-D-Arg-Dmt-Lys(NαMe)-Phe(NMe)-NH2;
H-D-Arg-Dmt-Lys(NαMe)-Phe-NH2;
H-D-Arg-Dmt-Lys-Phe(NMe)-NH2;
H-D-Arg-Dmt-Lys-Phe-Sar-Gly-Cys-NH2;
H-D-Arg-Dmt-LysΨ[CH2-NH]Phe-NH2;
H-D-Arg-Dmt-Ψ[CH2-NH]Lys-Phe-NH2;
H-D-Arg-Dmt-Ψ[CH2-NH]Lys-Ψ[CH2-NH]Phe-NH2;
H-D-Arg-Ψ[CH2-NH]Dmt-Lys-Phe-NH2;
His-Tyr-D-Arg-Trp-Lys-Phe-D-Asp-Ala-Arg-Cys-D-Tyr-His-Phe-D-Lys-Tyr-His-Ser-NH2;
Lys-D-Arg-Tyr-NH2;
Lys-D-Gln-Tyr-Arg-D-Phe-Trp-NH2;
Lys-Dmt-D-Arg-NH2;
Lys-D-Phe-Arg-Dmt-NH2;
Lys-D-Phe-Arg-Tyr-NH2;
Lys-Phe-NH2;
Lys-Trp-D-Tyr-Arg-Asn-Phe-Tyr-D-His-NH2;
Met-Tyr-D-Arg-Phe-Arg-NH2;
Met-Tyr-D-Lys-Phe-Arg;
Phe-Arg-D-His-Asp;
Phe-D-Arg-2′6′-Dmt-Lys-NH2;
Phe-D-Arg-D-Phe-Lys-NH2;
Phe-D-Arg-His;
Phe-D-Arg-Lys-Trp-Tyr-D-Arg-His;
Phe-D-Arg-Phe-D-Lys-NH2;
Phe-D-Arg-Phe-Lys-NH2;
Phe-D-Dmt-Arg-Lys-NH2;
Phe-D-Tyr-Arg-Lys-NH2;
Phe-Lys-Dmt-NH2;
Phe-Phe-D-Tyr-Arg-Glu-Asp-D-Lys-Arg-D-Arg-His-Phe-NH2;
Phe-Tyr-Lys-D-Arg-Trp-His-D-Lys-D-Lys-Glu-Arg-D-Tyr-Thr;
Thr-Gly-Tyr-Arg-D-His-Phe-Trp-D-His-Lys;
Thr-Tyr-Arg-D-Lys-Trp-Tyr-Glu-Asp-D-Lys-D-Arg-His-Phe-D-Tyr-Gly-Val-Ile-D-His-Arg-Tyr-Lys-NH2;
Trp-D-Lys-Tyr-Arg-NH2;
Trp-Lys-Phe-D-Asp-Arg-Tyr-D-His-Lys;
Tyr-Asp-D-Lys-Tyr-Phe-D-Lys-D-Arg-Phe-Pro-D-Tyr-His-Lys;
Tyr-D-Arg-NH2;
Tyr-D-Arg-Phe-Lys-Glu-NH2;
Tyr-D-Arg-Phe-Lys-NH2;
Tyr-D-His-Phe-D-Arg-Asp-Lys-D-Arg-His-Trp-D-His-Phe;
Tyr-D-Phe-Arg-Lys-NH2;
Tyr-His-D-Gly-Met;
and
Val-D-Lys-His-Tyr-D-Phe-Ser-Tyr-Arg-NH2,
and further comprising one or more additional active agents selected from the group consisting of cyclosporine, a cardiac drug, an anti-inflammatory, an anti-hypertensive drug, an antibody, an ophthalmic drug, an antioxidant, a metal complexer, and an antihistamine.

105 more elements

Facts

Application

14/899,439Filed 24 Jun 2014 · us provisional application

Priority

27 Jun 2013

Published

US 2016/0151446 A12 Jun 2016

Granted

21 May 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 38/07
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: tetrapeptides
A61K 38/05
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: dipeptides
A61K 38/06
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: tripeptides
A61K 38/08
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: peptides having 5 to 11 amino acids